Evotec shows weak June performance, analyst consensus points above current shares

Evotec starts the week with a muted share price and a clear analyst consensus. The biotech group trades well below average targets while technical indicators remain cautious.

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 12:51.

Evotec (DE0005664809) opens this Tuesday with weak recent share performance while trading on Xetra and regional German venues. Consensus data show the biotech stock changing hands clearly below the average analyst price target.

What the consensus implies

On wallstreet-online, Evotec shares are quoted around 4.59 euros on 23 June, leaving the stock roughly 42 percent below the 52-week high and about 16 percent above the 52-week low. The one-year performance stands at approximately minus 30 percent on this data set.

According to the same overview, 31 analysts cover Evotec, with an average price target of about 8.45 euros per share. This implies an upside of roughly 85 percent versus the current level, even after a monthly decline of more than 12 percent in June.

How analysts and traders view the stock

Finanzen.net shows Evotec shares at 4.59 euros on the Stuttgart exchange at mid-morning, a day-on-day move of around minus 0.7 percent. The site also highlights estimates and expectations for the stock, confirming a cautious near-term picture despite the higher average target.

For the US-traded Evotec ADR (ticker EVO on NASDAQ), TradingKey reports a closing price of 2.64 US dollars on 22 June, up just over 3 percent for that session. The technical dashboard there classifies the overall signal as Sell based on moving averages, with six sell and no buy signals on the MA5 to MA200 set.

How Evotec earns its money

Evotec develops and operates research alliances and development partnerships for new drug candidates, working with global pharma and biotech companies. The business is structured into EVT Execute, which provides integrated discovery and development services, and EVT Innovate, which advances proprietary and co-owned therapeutic projects.

Where Evotec shares trade now

The Evotec shares (DE0005664809) trade on 2026-06-23, 10:32, on German venues around 4.59 euros per share, based on wallstreet-online and finanzen.net indications.

Key data on the Evotec shares

• Company: Evotec SE
• ISIN: DE0005664809
• WKN: 566480
• Ticker: EVT
• Trading venue: Xetra
• Price (as of 2026-06-23, 10:32): 4.59 EUR
• Market cap: 0.94 billion EUR (as of 2026-06-22)
• Sector / industry: Biotechnology & Medical Research
• Index membership: not in DAX family benchmark indices
• Next earnings date: not officially scheduled

This text is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities.